RhumbLine Advisers’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-152,126
| Closed | -$639K | – | 4424 |
|
|
2023
Q1 | $639K | Buy |
152,126
+7,730
| +5% | +$32.5K | ﹤0.01% | 2322 |
|
|
2022
Q4 | $868K | Buy |
144,396
+2,481
| +2% | +$14.9K | ﹤0.01% | 2212 |
|
|
2022
Q3 | $826K | Buy |
141,915
+15,381
| +12% | +$89.5K | ﹤0.01% | 2245 |
|
|
2022
Q2 | $755K | Buy |
+126,534
| New | +$755K | ﹤0.01% | 2278 |
|
|
2019
Q2 | – | Sell |
-64,749
| Closed | -$63K | – | 3086 |
|
|
2019
Q1 | $63K | Sell |
64,749
-1,330
| -2% | -$1.29K | ﹤0.01% | 2906 |
|
|
2018
Q4 | $49K | Buy |
66,079
+20,630
| +45% | +$15.3K | ﹤0.01% | 2945 |
|
|
2018
Q3 | $98K | Sell |
45,449
-3,250
| -7% | -$7.01K | ﹤0.01% | 2871 |
|
|
2018
Q2 | $243K | Buy |
+48,699
| New | +$243K | ﹤0.01% | 2644 |
|
|
2016
Q2 | – | Sell |
-19,555
| Closed | -$104K | – | 3114 |
|
|
2016
Q1 | $104K | Buy |
19,555
+2,072
| +12% | +$11K | ﹤0.01% | 2887 |
|
|
2015
Q4 | $215K | Buy |
17,483
+2,894
| +20% | +$35.6K | ﹤0.01% | 2755 |
|
|
2015
Q3 | $213K | Buy |
14,589
+527
| +4% | +$7.69K | ﹤0.01% | 2758 |
|
|
2015
Q2 | $274K | Sell |
14,062
-45
| -0.3% | -$877 | ﹤0.01% | 2722 |
|
|
2015
Q1 | $255K | Buy |
14,107
+3,630
| +35% | +$65.6K | ﹤0.01% | 2701 |
|
|
2014
Q4 | $247K | Buy |
10,477
+325
| +3% | +$7.66K | ﹤0.01% | 2690 |
|
|
2014
Q3 | $246K | Hold |
10,152
| – | – | ﹤0.01% | 2640 |
|
|
2014
Q2 | $285K | Buy |
10,152
+1
| +0% | +$28 | ﹤0.01% | 2636 |
|
|
2014
Q1 | $345K | Buy |
10,151
+100
| +1% | +$3.4K | ﹤0.01% | 2447 |
|
|
2013
Q4 | $193K | Hold |
10,051
| – | – | ﹤0.01% | 2833 |
|
|
2013
Q3 | $165K | Buy |
10,051
+100
| +1% | +$1.64K | ﹤0.01% | 2843 |
|
|
2013
Q2 | $104K | Buy |
+9,951
| New | +$104K | ﹤0.01% | 3236 |
|